Adam Levy
Investor Relations Contact bei ALAUNOS THERAPEUTICS, INC.
Profil
Adam D.
Levy is currently the Executive Director-Investor Relations at Gilead Sciences, Inc., the Director at Vesselon, Inc., the Senior VP-Communications & Investor Relations at Turning Point Therapeutics, Inc., the EVP-Corporate Development & Investor Relations at Alaunos Therapeutics, Inc., and the SVP, Head-Investor Relations & Corporate Affairs at Acrivon Therapeutics, Inc. Previously, he worked as the Senior Vice President-Investor Relations at Zentalis Pharmaceuticals, Inc. Dr. Levy completed his undergraduate and doctorate degrees at the University of Illinois and holds an MBA from the Kellogg School of Management.
Aktive Positionen von Adam Levy
| Unternehmen | Position | Beginn |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Investor Relations Contact | 01.11.2020 |
| TURG POIN | Investor Relations Contact | 08.11.2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
| ACRIVON THERAPEUTICS, INC. | Investor Relations Contact | 20.07.2023 |
Vesselon, Inc.
 Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Director/Board Member | - |
Ehemalige bekannte Positionen von Adam Levy
| Unternehmen | Position | Ende |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Ausbildung von Adam Levy
| University of Illinois | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Health Technology |
